Zydus receives final approval from the USFDA for Erythromycin Tablets USP, 250 mg and 500 mg

Zydus Lifesciences Limited (including its subsidiaries / affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) for Erythromycin Tablets USP, 250 mg and 500 mg (USRLD: Erythromycin Tablets).

Erythromycin Tablets USP, 250 mg and 500 mg are used to prevent and treat infections in many different parts of the body, including respiratory tract infections, skin infections, diphtheria, intestinal amebiasis, acute pelvic inflammatory disease, legionnaire's disease, pertussis and syphilis. The drugs will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad (India).

Erythromycin Tablets USP, 250 mg and 500 mg had annual sales of USD 25.1 mn in the United States (IQVIA MAT Dec. 2022).

The group now has 350 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 468.95 as compared to the previous close of Rs. 471.30. The total number of shares traded during the day was 10951 in over 863 trades.

The stock hit an intraday high of Rs. 475.15 and intraday low of 467.35. The net turnover during the day was Rs. 5166485.00.

(*as of 31st December 2022)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 FinalApproval USFDA ErythromycinTablets